Probenecid
As of the edition of 20 October 2026, Probenecid is a small molecule: marketed, first approved in 1982 (US); acts on SLC22A11, SLC22A6 and SLC22A8; no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Benemid
- First approved
- 1 January 1982 (US)
- Approvals on record
- 7 in 3 regions
- Holder of the most recent approval
- Iterum Therapeutics; 6 holders in all
- Registered trials
- 57, 2 stopped early
- Disease areas
- Infections; Urinary and reproductive; Immune system; Nutrition and metabolism; Eye; Nervous system
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Iterum Therapeutics holds a later exclusivity on its own new formulation or combination product, ending 2034; it does not protect the original drug.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Probenecid.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 8 | 0 | 0 |
| Phase 1 | 30 | 26 | 2 | 1 |
| Phase 2 | 7 | 5 | 2 | 0 |
| Phase 3 | 6 | 5 | 1 | 0 |
| Phase 4 | 5 | 4 | 0 | 1 |
| All trials | 57 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Lipomed | Applicant | 2005 to now |
| Merck & Co. | Applicant and Lead sponsor of trials | 2026 to now |